Article
[Exploring the Possibility of New Biomarkers of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer (NSCLC)].
Gan to kagaku ryoho. Cancer & chemotherapy - 1 Sept 2017
Owada Yuki, Inoue Takuya, Watanabe Yuzuru, Fukuhara Mitsuro, Yamaura Takumi, Muto Satoshi, Matsumura Yuki, Hasegawa Takeo, Tanaka Daisuke, Kanno Ryo, Ito Emi, Nanamiya Hideaki, Imai Junichi, Isogai Takao, Watanabe Shinya, Suzuki Hiroyuki
Abstract excerpt
Mutation burden in a tumor, presumably involving neo-antigens in the tumor tissue, is also thought to be one of the better predictors for the efficacy of immune checkpoint inhibitors. However, it is difficult to analyze the mutation burden routinely in the clinic. Here, we describe more convenient factors that can be used as surrogate markers of mutation burden. Ninety-four patients with NSCLC who underwent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.